Navigation Links
PSA TestingHow Much is Too Much?


For more than 20 years, the PSA test has been widely used as the gold standard for prostate cancer screening. In one of the most dramatic reversals in recent diagnostic science, a recent study at Stanford University School of Medicine and findings by other researchers have now put the utility of the procedure in grave doubt.

Indeed, The PSA era is over in the United States, said Thomas Stamey, MD, professor of urology and lead author of the study published in the October 2004 issue of the Journal of Urology. Our study raises a very serious question of whether a man should even use the PSA test for prostate cancer screening any more, Stamey said. The researchers opinion carries great influence, since it was Stameys work in the late 80s that propelled PSA testing into widespread use (and prompted the corresponding practice of routinely removing prostates in response to high PSA levels).

As time has passed, however, Stamey has concluded that PSA testing is unable to predict the extent or severity of prostate cancer but, instead, provides a measure of benign prostatic hyperplasia.

Mark Twain once famously quipped that, The report of my death was an exaggeration. The death knell of PSA may also have sounded too soon, since the assay is likely to continue to provide useful data, albeit in far less universal applications. Stamey and his colleagues identified two important and continuing uses for PSA testing in their recent paper. They noted that PSA levels quite accurately correlate with prostate size and that the test thus serves as a direct measure of benign prostatic hyperplasia. Stamey noted that the assay is also helpful for monitoring patients following prostate removal because it can indicate residual prostate cancer that has metastasized.

As with many disease screens, PSA tests now range from assay reagents used in multi-function clinical laboratory analyzer systems to rapidly performed, self-contained kits suitable for point of care use, to mail-in specimen collection kits available for clinical or home screenings.

Bio-Quant, Inc., San Diego, Calif., manufactures the OneStep PSA InstaTest designed to detect PSA concentration in whole blood or serum in concentrations as low as four ng/ml within 15 minutes. The result is read visually by observing symbols that develop during the test in a result window. The company says that comparative studies have demonstrated that relative sensitivity of InstaTest PSA is 100 percent, and its relative specificity is 98.5 percent.

Beckman Coulter, Inc., Fullerton, Calif., produces the Hybritech PSA Test and, as a confirmatory follow-up, the Hybritech free PSA Test. The Hybritech PSA test was the first assay approved by FDA for the detection of prostate cancer when used in combination with digital rectal examination (DRE) in men aged 50 years or older. The assay provides equimolar PSA measurement based on a monoclonal antibody pair. The company lists analytical sensitivity at <0.008 ng/mL ; measurement range to 150 ng/mL and precision at < 5% CV across the assay range. Time to first result is 20 minutes, using a serum sample of 25 L.

In the early 1990s, it was demonstrated that measuring the ratio of free to total PSA could further help in distinguishing prostate cancer from benign prostate disease. The Hybritech free PSA testalso the first test of its kind to receive approvalhelps determine the percent of free PSA and thereby improve the accuracy of prostate cancer detection while eliminating a projected 20 percent of all prostate biopsies . The free PSA test is used following a non-suspicious DRE and a total PSA test that shows moderately elevated PSA levels (between four and 10 ng/mL) in men aged 50 years and older.

Analytical sensitivity for this assay at <0.005 ng/mL ; measurement range to 20 ng/mL and precision at UniMed LLC, Natick, Mass., manufactures a Prostate Specific Antigen (PSA); Prostate Cancer Test collection kit that includes a fingertip blood sample stylet, specimen card. The user sends the prepaid mailer to the companys laboratory where it is analyzed using the Tandem PSA method for total PSA. The results are returned by mail.

Craig Medical Distribution, Inc., Vista, Calif., produces another FDA-approved sample collection kit: the PSA4 Screening Test, a quantitative assay for a whole blood sample. As with the UniMed product, a fingertip blood sample is enclosed in a pre-addressed, postage paid mailer and sent to the laboratory where the sample is tested, the results are tabulated in report form, reviewed by a physician and returned within five days.

Given the widespread prevalence of prostate cancer the search for markers more accurate than PSA are now being widely sought. Prior to their availability, PSA testing, while in a far more limited role, will continue to perform useful work.
'"/>




Related medicine technology :

1. Novel Human Tissue Transgenic Cancer Model May Offer Significant Advance Toward Accurately Modeling Human Cancer
2. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
3. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
4. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
5. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
6. Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference
7. Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference
8. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
9. Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
10. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
11. Data Show FluMist May Reduce Seasonal Influenza Burden Among Children in School, Daycare Settings

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):